Paper Details

  1. Home
  2. Paper Details

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.

Author: ArguetaR, CaplanR H, KnickerbockerR K, LufkinE G, NickelsenT, RiggsB L, WhitakerM D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Raloxifene therapy is well tolerated, reduces serum lipids, and does not stimulate the uterus or breasts. It has beneficial effects on bone, although these appear to be of a smaller magnitude than have been reported with estrogen therapy.
Paper Details　
Original Abstract of the Article :
Raloxifene is a selective estrogen receptor modulator that in experimental animals acts as an estrogen receptor antagonist in breast and endometrium but as an estrogen receptor agonist in the skeletal and cardiovascular systems. We conducted a 1-year prospective, randomized, double-blind trial in 14...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1359/jbmr.1998.13.11.1747

データ提供：米国国立医学図書館（NLM）

Raloxifene: A New Hope for Postmenopausal Osteoporosis

Postmenopausal osteoporosis is a common condition characterized by bone loss, leading to an increased risk of fractures. This research investigates the efficacy and safety of raloxifene, a selective estrogen receptor modulator, in the treatment of established postmenopausal osteoporosis.

Raloxifene: A Bone-Strengthening Agent

The study found that raloxifene therapy is well-tolerated, reduces serum lipids, and has beneficial effects on bone mineral density (BMD), albeit to a lesser extent than estrogen therapy. This research provides valuable insights into the potential of raloxifene as a treatment option for postmenopausal osteoporosis.

A New Approach to Bone Health

Just as a camel adapts to the harsh desert environment, researchers are constantly seeking new strategies to maintain bone health. This research highlights the potential of raloxifene, a selective estrogen receptor modulator, as a promising treatment option for postmenopausal osteoporosis. The authors emphasize its safety and efficacy in improving BMD and reducing the risk of fractures.

Dr. Camel's Conclusion

Imagine a camel crossing a vast desert, its strong bones supporting its journey. This research is like a desert oasis, offering a new solution for maintaining bone health. It highlights the potential of raloxifene, a selective estrogen receptor modulator, as a promising treatment option for postmenopausal osteoporosis. The authors emphasize its safety and efficacy in strengthening bones and reducing the risk of fractures.
Date :
  1. Date Completed 1999-02-09
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

9797484

DOI: Digital Object Identifier

10.1359/jbmr.1998.13.11.1747

Related Literature

Article Analysis
・Effects of raloxifene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.